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Abstract 
What can be expected in normal aging, and where does normal aging stop and pathological 
neurodegeneration begin? With the slow progression of age-related dementias such as Alzheimer’s 
Disease (AD), it is difficult to distinguish age-related changes from effects of undetected disease. We 
review recent research on changes of the cerebral cortex and the hippocampus in aging and the 
borders between normal aging and AD. We argue that prominent cortical reductions are evident in 
fronto-temporal regions in elderly even with low probability of AD, including regions overlapping the 
default mode network. Importantly, these regions show high levels of amyloid deposition in AD, and 
are both structurally and functionally vulnerable early in the disease. This normalcy-pathology 
homology is critical to understand, since aging itself is the major risk factor for sporadic AD. Thus, 
rather than necessarily reflecting early signs of disease, these changes may be part of normal aging, 
and may inform on why the aging brain is so much more susceptible to AD than is the younger brain. 
We suggest that regions characterized by a high degree of life-long plasticity are vulnerable to 
detrimental effects of normal aging, and that this age-vulnerability renders them more susceptible to 
additional, pathological AD-related changes. We conclude that it will be difficult to understand AD 
without understanding why it preferably affects older brains, and that we need a model that 
accounts for age-related changes in AD-vulnerable regions independently of AD-pathology. 
 
 
Keywords normal aging; Alzheimer’s disease (AD); default mode network (DMN); cerebral cortex; 
hippocampus; amyloid; 
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1. Introduction 
The major risk factor for Alzheimer’s Disease (AD) is age, with a sharp increase in incidence after 60 
years (Kawas et al., 2000). This has inspired many researchers to propose that to understand AD, we 
must understand its inherent relationship to aging (Herrup, 2010). Why is the aging brain so 
susceptible to AD, compared to the middle-aged or young brain? What features distinguish normal 
brain changes from those seen in early AD? How should we understand the fact that three of the 
major symptoms of AD observed in vivo – disruption of episodic memory function (Koivisto et al., 
1995, Nyberg et al., 2012), brain atrophy (Raz et al., 2005, Driscoll et al., 2009, Fjell et al., 2009a) and 
accumulation of amyloid protein (Morris et al., 2010) – are also found in many presumably healthy 
elderly? Given these commonalities, it can be argued that AD cannot be understood separately from 
its major risk factor – age. However, we suggest that this statement can also be reversed: if we 
understand why the older brain is susceptible to AD, we may have a better chance of understanding 
brain aging itself. With the aging of the population, a comprehensive understanding of normal, non-
demented changes in brain and cognition is arguably as important as understanding AD.  
 
How the link between aging and AD should be understood is thus a major question in contemporary 
neuroscience. However, it is not obvious that studying the relationship between the two is the best 
starting point for understanding either phenomenon. Some argue that AD should be viewed as a 
disease with distinct etiology and neuropathology, separate from normal aging, and that it is less 
fruitful to view AD in light of normal age changes (Nelson et al., 2011). AD may be driven by factors 
less related to aging per se, for instance differences in amyloid precursor protein expression (APP) 
(Nelson et al., 2011), from which the presumably most toxic form of amyloid (Aβ42) originates. 
However, we have still not understood the role of amyloid in brain atrophy and cognitive decline. 
Current models of the role of amyloid in AD, as for instance reflected in the proposed diagnostic 
guidelines from the National Institute of Aging - Alzheimer’s Association (NIA-AA) (Jack et al., 2011, 
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Sperling et al., 2011a) and the popular ‘dynamic biomarker model’ (Jack et al., 2010a, Jack et al., 
2013), suggest that the influence of amyloid is greatest in very early phases – at a stage where 
cognitive and clinical symptoms are not yet detected. When accelerated brain atrophy and cognitive 
decline become evident, the therapeutic window for anti-amyloid drugs may very well be closed. 
Thus, it is absolutely necessary to study the relationship between amyloid, brain integrity and 
memory in healthy elderly if the role of amyloid in neurodegeneration and cognitive decline is to be 
understood. Animal models of AD are not characterized by the massive brain atrophy that correlates 
with memory problems in AD patients, and therefore can provide only limited insight into 
relationships between amyloid, brain integrity and episodic memory decline in non-demented older 
adults.  
 
In the present paper, we review recent research on cortical and hippocampal changes in normal 
aging, the relationship between changes in normal aging vs. early AD, and the role played by amyloid. 
First, we will discuss the characteristics of presumably normal brain aging. What kind of macroscopic 
brain changes can be expected in older adults without dementia, and what consequences do these 
brain changes have for cognitive function? We try to identify and evaluate some of the proposed 
major organizing principles for brain aging, such as the theory of retrogenesis or the principle of “last 
in, first out”. In the cognitive domain, we focus especially on episodic memory, which is of interest 
because it is affected both in normal aging and very early in AD. Second, we investigate similarities 
and differences in the pattern of brain atrophy between normal aging and AD, with a special focus on 
comparisons between AD patients and elderly individuals with low AD-risk. Finally, we discuss the 
role of amyloid in brain atrophy and cognition, and evaluate current available knowledge related to 
the question of why brain aging is associated with the dramatic increase in AD-risk.  
 
2. What is normal in normal aging? 
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2.1 Magnitude, pattern and timing of change 
Reductions in specific cognitive abilities like mental speed (Salthouse, 1996), executive function 
(Connelly et al., 1991, Schretlen et al., 2000, Rabbitt et al., 2001) and episodic memory (Salthouse, 
2003, Buckner, 2004, Nyberg et al., 2012) are commonly experienced in aging, while verbal abilities 
and world knowledge are typically maintained (Park and Reuter-Lorenz, 2009). However, there is 
disagreement about whether longitudinal changes in older adults reflect continuous ongoing 
processes starting in young adulthood or whether changes begin in middle age or beyond. Closely 
related to this is an unsettled discussion about whether changes observed in cross-sectional studies 
reflect real ongoing change within individuals  (Salthouse, 2009) or arise from methodological 
artifacts (Schaie, 2009, Nyberg et al., 2012). Cross-sectional studies may suffer from cohort effects, 
and, potentially more seriously, different recruitment bias across age-groups. For instance, most 
studies are based on convenience samples, and there may be systematic differences in individuals 
who are recruited for, and agree to participate in, research at younger ages and older ages. For 
example, young participants are often college students, middle-aged participants may be more likely 
to be unemployed or under-employed, and older participants may be recruited from senior centers. 
The older age group may be biased by participants motivated to volunteer due to concerns about 
their cognitive abilities, or, alternatively, only the superior functioning older adults volunteer or are 
accepted into the study due to strict exclusion criteria. Thus these three age groups may differ in 
critical characteristics, which may affect the estimated age-trajectories. This is referred to as 
covariance between age and sampling bias. Longitudinal studies are, in principle, not affected by this 
bias and can measure change over time within individuals. However, longitudinal studies too have 
limitations that can influence the results – such as selective attrition and test-retest effects that may 
be larger than the change across time points (Salthouse, 2012). Adding to this, few longitudinal 
studies sample the entire adult age-span, precluding estimations of change rates as a function of age. 
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Despite the limitations of cross-sectional and longitudinal study designs, there is a consensus that  
episodic memory, which is of special focus in the present review, declines from about the age of 50-
60 years on a population basis (Nyberg et al., 2012), although earlier decrements cannot be ruled out. 
In a very interesting study, longitudinal trajectories in episodic memory were mapped over 15 years 
in more than 1500 participants from the Betula study (Josefsson et al., 2012). Using a random-effects 
pattern-mixture model, the authors were able to divide the participants into three groups in terms of 
memory change – maintainers (18%), those who showed age-typical decline (68%) and decliners 
(13%) (see Figure 1). Physical activity, being female and living with someone increased the likelihood 
of being a maintainer, while lower education, not being employed and being male increased 
likelihood of being a decliner. Further, the authors corrected the age-memory reduction function for 
the effects of selective attrition. Correcting for selective attrition revealed a much steeper decline in 
episodic memory with increasing age than merely analyzing the available raw data. This indicates 
that studies may actually under-estimate the true age-decline due to selective attrition in 
longitudinal designs, or, likely, covariance between selection biases and age in cross-sectional. 
Carefully conducted longitudinal studies yield opportunities for correcting for these biases, revealing 
truer age-functions. 
 
[Insert Figure 1 about here] 
 
A popular view is that at least some portion of the age-changes in cognitive function is caused by 
structural brain changes. Cross-sectional correlations between brain volume and cognitive function 
cannot alone be used to justify such claims, and other types of cross-sectional evidence, e.g. cross-
sectional mediation analysis, also have caveats (Rabbitt, 2011, Raz and Lindenberger, 2011, Salthouse, 
2011). Detailed mapping of regional longitudinal brain changes, which then can be correlated with 
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longitudinal cognitive changes, is a more promising avenue for understanding the neurobiological 
foundation for age-related decrements in cognitive function.  
 
Compared to cognitive testing, an advantage with MRI is that re-test effects are likely to be minute, 
and follow-up examinations at short intervals are highly feasible. With high-quality MR-scans and 
state-of-the-art analysis tools (Reuter et al., 2010, Holland and Dale, 2011, Holland et al., 2012b, 
Reuter et al., 2012), brain changes can be detected reliably and monitored over intervals as short as 
one year or less even in healthy elderly (Fjell et al., 2009a, Murphy et al., 2010). Although 
longitudinal studies cannot fully replace cross-sectional studies in brain aging research for a number 
of practical reasons, such as the relatively short life-expectancy of MR-scanners and continual 
advances in technology, repeated MRIs yield a unique tool to monitor brain changes naturally 
occurring among older adults.  
 
Reductions in gross brain volume over time are now well-documented, with annual decreases on the 
order of 0.2 - 0.5% (Scahill et al., 2003, Ezekiel et al., 2004, Enzinger et al., 2005, Fotenos et al., 2005, 
Hedman et al., 2012). Significant longitudinal change has been observed across almost the entire 
cerebral cortex (Driscoll et al., 2009, Fjell et al., 2009a), but with substantial heterogeneity across 
regions. Traditionally, the frontal lobes have been regarded as especially vulnerable to normal age-
changes, inspiring frontally-based theories of cognitive aging (West, 1996, Robbins et al., 1998, 
Rabbitt, 2005). Evidence is accumulating, however, that in healthy older adults, temporal areas 
undergo reductions over time of comparable magnitude to the frontal changes (Driscoll et al., 2009, 
Fjell et al., 2009a, Raz et al., 2010, Pfefferbaum et al., 2013). Annual atrophy rates of 0.79% to 2.0% 
for the hippocampus (Jack et al., 1998, Scahill et al., 2003, Ezekiel et al., 2004, Raz et al., 2005, Du et 
al., 2006, Fjell et al., 2009a) and of 0.3% to 2.4% for the entorhinal cortex (Du et al., 2003, Ezekiel et 
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al., 2004, Raz et al., 2005, Du et al., 2006, Fjell et al., 2009a) have been reported. Thus, age-related 
atrophy is not restricted to the frontal lobes. 
 
Age-related changes in cortical volume are illustrated in Figure 2, which shows one-year percentage 
change in healthy elderly participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
(see www.adni-info.org). These participants remained free of a mild cognitive impairment (MCI) or 
AD diagnosis for three years following the baseline scan. As can be seen, cortical volume reductions 
are found across most of the brain surface, with annual change rates of around 0.5% in most regions. 
Figure 2 also shows this annual change expressed in standard deviations, highlighting the relative 
degree of change across different regions (Z-transformed maps). The frontal and the temporal lobes 
stand out with the highest degree of relative change, with substantial change observed also in the 
medial parietal area (precuneus and the adjacent retrosplenial and posterior cingulate cortices). This 
predominant fronto-temporal pattern of atrophy is in accordance with the results of several 
independent longitudinal studies using different methods for quantification of brain change. As we 
discuss below, this has implications for how we should understand the macro-structural correlates of 
decline in specific cognitive abilities in normal aging, and how we should conceptualize the 
differences between normal aging and age-related neurodegenerative disease like AD. 
 
[Insert Figure 2 about here] 
 
Longitudinal studies can track within-person changes in brain structures over time. However, no 
longitudinal MR-studies can follow the same participants over extended time-periods.. Thus, to 
investigate the effect of age across the life-span on brain changes, combinations of longitudinal and 
cross-sectional designs seem to be the optimal solution. Among such studies, several have found 
modest acceleration of regional decline with increasing age (Raz et al., 2004a, Raz et al., 2004b, Raz 
9 
 
et al., 2005, Du et al., 2006, Driscoll et al., 2009, Fjell et al., 2009a, Raz et al., 2010, Schuff et al., 2010, 
Thambisetty et al., 2010, Holland et al., 2012a, Taki et al., 2013, Pfefferbaum et al., 2013). Thus, 
there is a tendency that the rate of atrophy in specific brain regions is higher in older adults than in 
middle-aged adults. However, very few longitudinal studies have sampled the entire adult life-span, 
and this hinders direct comparisons between young and older adults although important exceptions 
exist (e.g. (Raz et al., 2005, Taki et al., 2013, Pfefferbaum et al., 2013)). This is the major strength of 
the cross-sectional design. Dozens of cross-sectional studies have reported that different macro-
structural measures of the cerebral cortex are negatively correlated with age across the adult life-
span. Negative correlations between cortical thickness and age have been reported in all regions 
(Fjell et al., 2013d), exceeding -.70 in the most vulnerable areas. As long as the MR scans are of good 
quality, the method used to quantify cortical reductions is identical and the sample size is reasonably 
large, high consistency can be observed across studies (Fjell et al., 2009b). In Figure 3, Pearson 
correlations between age and cortical thickness in a large sample of healthy adults are shown. Strong 
correlations are seen in the frontal cortex, both laterally and medially, but also in other regions, such 
as the lateral temporal cortex. 
 
[Insert Figure 3 about here] 
 
Cross-sectional studies of cortical thickness and volume usually find mainly linear age-relationships, 
although tendencies towards accelerating or reduced estimated decline with increasing age are 
sometimes reported for specific regions, such as accelerated decline of the entorhinal and the lingual 
cortex with age, and decreasing decline in anterior parts of the cingulate (Fjell et al., 2013d) (see 
Figure 4). This is in contrast to the trajectory for hippocampal volume, which almost invariably shows 
accelerated decline with higher age across studies. In Figure 5, typical age-trajectories for the volume 
of the hippocampus and for the rest of the cerebral cortex observed in cross-sectional studies are 
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illustrated. While total cortical volume declines almost linearly from 20 years, hippocampus is 
relatively stable until about the age of 60 years, after which the trajectory indicates prominent loss.  
 
[Insert Figure 4 and Figure 5 about here] 
 
More longitudinal studies including participants from the entire adult lifespan are expected, and will 
likely advance our knowledge about this critical question over the next few years. A challenge, 
however, is that the potential cross-sectional fallacy of covariance between sampling bias and age, i.e. 
that the oldest participants are not representative of the younger population, will carry over to the 
combined cross-sectional and longitudinal design. However, a way to account for this effect by use of 
multiple samples has been suggested (see e.g. (Schaie and Hofer, 2001)).  
 
Two recent studies have used longitudinal data to demonstrate flaws in apparent cross-sectional 
trends. Nyberg et al. followed a sample of elderly over six years, measuring brain activation during a 
semantic categorization task (Nyberg et al., 2010b). The cross-sectional analyses indicated frontal 
over-recruitment in aging. In contrast, the longitudinal analyses revealed frontal reductions over time, 
and showed that the cross-sectional over-recruitment could be accounted for by a select sample of 
high-performing elderly. We recently made a similar observation in a combined longitudinal and 
cross-sectional study of cortical thickness change in aging (Fjell et al., 2013d). In a sample of healthy 
elderly adults from ADNI, we observed a positive correlation between thickness and age in the 
cingulate cortex, especially the anterior parts. This has been found previously in several independent 
cross-sectional samples (Salat et al., 2002, Fjell et al., 2009b). However, when we examined the 
follow-up data for the same participants, consistent thinning was found throughout the cerebral 
cortex, including the entire anterior cingulate. The results are illustrated in Figure 6. In addition, 
there was a general down-scaling of estimated change in the cross-sectional compared to the 
11 
 
longitudinal results. This indicates that cross-sectional studies may under-estimate rather than 
exaggerate real change, an observation also made previously (Raz et al., 2005). Similar observations 
have been made for cognitive functions like episodic memory, where cross-sectional studies have 
found almost linear decline from 20 to 80 years of age but practice-adjusted longitudinal data have 
shown preservation of function until 60 years of age (Nyberg et al., 2012). Actually, if the true age-
trajectory is non-linear, cross-sectional results may over-estimate the age-effect in the first part of 
adult life and under-estimate it in the second part. 
 
[Insert Figure 6 about here] 
 
With such discrepancies between cross-sectional and longitudinal results in mind, it is important to 
be cautious about inferences from one to the other. Still, the differences are not always as prominent 
as in these examples, and cross-sectional and longitudinal results often converge (Fjell et al., 2013d). 
Thus confirming results by use of both cross-sectional and longitudinal analyses will strengthen 
conclusions. 
 
2.2 How best to quantify brain change? 
Surface-based segmentation techniques allow structural cortical changes to be measured along 
several different dimensions, such as thickness, area, volume, gyrification and signal intensity or gray 
matter – white matter contrast. In recent years, more researchers have been conscious of the 
differences between these measures. Volume is the more complicated measure to interpret, since it 
is the product of two genetically independent metrics (thickness and area) (Panizzon et al., 2009), 
and is affected by fundamentally different neurobiological properties during development and 
evolution (Rakic, 2009, Rakic et al., 2009, White et al., 2010). Area has expanded tremendously 
during evolution, without comparable increase in thickness: a twofold difference in cortical thickness 
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between rodents and primates does not measure up to the 1000-fold difference in total cortical 
surface area between mice and humans (Rakic, 2009). In human adults, weak (Winkler et al., 2010) or 
even negative (Hogstrom et al., 2012) correlations between thickness and area have been observed. 
It has been suggested that myelin growth, both intracortically and in subcortical regions, may stretch 
the cortex tangentially to the surface (Seldon, 2005). This is hypothesized to contribute to 
disentangling of neighboring neuronal columns and enabling the relevant parts of the cortex to 
better differentiate afferent signal patterns increasing functional specialization (Seldon, 2007). This 
model provides one possible mechanistic and functional account for a negative relationship between 
cortical thickness and surface area. Few studies have systematically compared differences in age-
vulnerability between cortical thickness, area and volume, but there are indications that thickness is 
more affected than area (Hogstrom et al., 2012) (see Figure 7). In sum, although volume may be a 
sensitive measure of atrophy and age-related differences, the underlying neurobiological causes 
leading to volume reduction are difficult to identify due to the independence of the two constituting 
measures of cortical thickness and area. 
 
[Insert Figure 7 about here] 
 
There is discussion about whether changes in glucose metabolism in aging as evidenced by [F-
18]fluorodeoxyglucose positron emission tomography (FDG-PET) occurs prior to, at the same time as, 
or is a consequence of atrophy. While this discussion is outside the scope of this paper, it can be 
noted that glucose metabolism is reduced in normal aging, e.g. in anterior regions such as the 
anterior cingulate (Yoshizawa et al., 2013), and it is suggested that hypermetabolism in specific 
regions, e.g. anterior cingulate, as well as functional connectivity, are positively related to of 
cognitive reserve (Arenaza-Urquijo et al., 2013a). However, the relationship between degeneration, 
cognitive function and metabolism is not simple, as other studies have found hypermetabolism in 
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amyloid positive non-demented elderly, e.g. in the bilateral superior temporal gyrus (Johnson et al., 
2013). In a comprehensive study of age-changes in atrophy and metabolism based on the ADNI 
database, age- and symptom-severity dependent glucose metabolism both in temporal, parietal and 
precuneus regions was found in a sample of AD patients and healthy controls (Dukart et al., 2013). 
The authors further suggested a dissociation with larger effects on metabolism compared to atrophy 
in early phases of AD and the opposite pattern at more advanced stages. Targeted investigations into 
the relationship between changes in metabolism and atrophy has the potential to yield important 
insights into the cerebral changes in normal aging and their cognitive correlates.  
 
2.3 Principles of regional cortical age-changes: Development and evolution 
As reviewed above, cortical reductions are relatively global in normal aging, not being confined to 
specific regions. Still, substantial heterogeneity is seen, with several studies identifying fronto-
temporal areas as especially prone to the effects of aging. Attempts have been made to explain the 
regional differences in age-vulnerability based on different overarching principles. While some of 
these proposed principles capture critical aspects of brain aging, all also have substantial weaknesses. 
One popular view is that late-maturing regions are most vulnerable to age-changes, often referred to 
as the “last in, first out” or “retrogenesis” hypothesis. These areas tend to have a more complex 
cortical architecture than areas that develop early. The finding that late-maturing medial frontal 
areas, such as the medial orbitofrontal cortex (Gogtay et al., 2004, Tamnes et al., 2012), are highly 
vulnerable to aging has lead to the hypothesis of an anterior-to-posterior gradient of age 
vulnerability, which has been invoked to explain the decline in executive function often observed in 
healthy elderly samples (Gunning-Dixon and Raz, 2003, Head et al., 2009). For instance, while 
degeneration of the medial temporo-parietal memory network is characteristic for AD, change in a 
fronto-striatal network supporting executive functions has been proposed as a hallmark of healthy 
aging (Buckner, 2004, Head et al., 2005) (see Figure 8). Decline of executive functioning can impact 
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memory function, and contribute to memory problems in non-demented elderly. This can occur even 
in MCI patients. It has been shown that MCI patients with higher executive function perform better 
on episodic memory tests, with higher memory performance related to thicker cortices in regions 
outside the medial temporal lobe, including prefrontal regions  (Chang et al., 2010). From this view, 
even though reduction in episodic memory function is seen in both AD and healthy aging, this 
reduction could have partially different brain structural causes. Thus, the “last in, first out” model has 
many similarities to the traditional “frontal theory of aging” (West, 1996, Robbins et al., 1998, 
Rabbitt, 2005).  
 
[Insert Figure 8 about here] 
 
Although the “last in, first out” model is consistent with some of the data on brain aging, there are 
important discrepancies between the available data on cortical maturation and aging. This becomes 
especially evident when maturation and aging of the medial temporal lobes are compared. Medial 
temporal lobe structures are typically found to undergo relatively modest maturation after school 
age is reached (Shaw et al., 2008, Ostby et al., 2009, Tamnes et al., 2012, van Soelen et al., 2012), yet 
are strongly impacted by age, especially after 60 years (see Figures 4 and 5). Thus, in this respect, 
“the last in, first out” theory of brain maturation does not account for one of the most important 
features of cortical brain aging – the vulnerability of medial temporal regions.  
 
The ”last in, first out” hypothesis is based on a view that more complex brain areas, supporting 
higher-order cognitive functions such as executive functions, take longer to develop, follow more 
complex developmental trajectories (Shaw et al., 2008) and are more vulnerable to the negative 
effects of normal aging. A version of this hypothesis takes human evolution as a starting point 
instead of ontogenetic development, applying the same principles of cortical complexity and age-
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vulnerability. Human cortical surface area has expanded tremendously during evolution (Kaas, 2008), 
more than what can be explained by body size alone – a phenomenon referred to as encephalization 
(Fonseca-Azevedo and Herculano-Houzel, 2012). The adaptive benefits of improved general 
intellectual function likely underlie this expansion (Gibson, 2002, Sherwood et al., 2008). Cortical 
expansion during evolution is spatially heterogeneous, with large scaling effects in some regions and 
minute effects in others (Van Essen and Dierker, 2007). Interestingly, Hill et al. recently 
demonstrated similarities between cortical expansion in evolution and development (Hill et al., 2010) 
- evolutionary high expanding cortical areas tended to show high developmental expansion in 
childhood, suggesting that evolutionary factors have shaped ontogenetic cortical development. To a 
certain extent, cortical regions supporting mental capacities in which humans excel compared to 
other primates have expanded the most (Haug, 1987, Sherwood et al., 2008, Fjell et al., 2013b), and 
it has been suggested that human-specific cognitive adaptations are correlated with enlargement of 
the neocortex (Sherwood et al., 2008). Thus, it is possible that high-expanding cortical regions during 
evolution will have a protracted ontogenetic developmental course, tend to support higher-order 
late-maturing cognitive functions, and be more vulnerable to decline in normal aging.  
 
In Figure 9, cortical area expansion maps from macaque to humans, previously published in (Bardet 
et al., 2007, Hill et al., 2010), and longitudinal atrophy maps from healthy ADNI participants, are 
projected onto the same cortical surface and displayed on the same scale (Z scores). As can be seen, 
there is overlap between high-expanding cortical areas during evolution and areas that undergo 
rapid decline during normal aging. Contrasting annual percentage decline in regions of high, medium 
or low evolutionary expansion revealed clear differences in a dose-dependent manner. Annual 
percentage change in cortical volume increase from 0.23 to 0.41 and 0.53 from low to medium to 
high expansion regions. Overlap between evolutionary expansion and cortical age-vulnerability was 
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most prominent on the lateral surface, with high expansion and high rate of atrophy in the lateral 
temporal cortex, inferior regions of the parietal cortex and most of the lateral prefrontal cortex.  
 
[Insert Figure 9 about here] 
 
Medially, however, there are important differences. High expansion and high rate of atrophy are 
seen in parts of the superior frontal cortex and the anterior cingulum. Interestingly, the medial 
temporal lobes, including entorhinal and parahippocampal cortices, as well as posterior cingulate/ 
retrosplenial cortex and the precuneus, show a high degree of decline in normal aging, but relatively 
low expansion during evolution. Also, the most anterior part of the cingulate cortex, the subgenual 
cortex (Broadman area 25) shows substantial age-decline without high evolutionary expansion. 
Several of these areas belong to the allocortex or archicortex, which is phylogenetically older and has 
a cellular organization that deviates from the typical six-layered structure of most of the rest of the 
neocortex. For instance, parts of the cingulate cortex have a less distinct laminar differentiation (Vogt 
et al., 1995), lacking the internal granular layer (IV). These evolutionary low-expanding, age-
vulnerable cortical regions overlap well with the Papez circuit, important in normal memory function, 
and also with areas previously found to show simpler developmental trajectories (Shaw et al., 2008).  
 
A note of caution must also be included in a discussion of phylogenetic brain expansion, because it is 
challenging to draw inferences about brain evolution from inter-species comparisons. For instance, it 
has been argued that comparison of proportional size of different brain areas across species conflate 
selective enlargement with allometric scaling, and consequently that it is invalid to infer that humans 
are specialized for frontal lobe functions in particular compared to other species (Barton and Venditti, 
2013). Due to allometric constraints on connectivity caused by the fast increase in white matter 
during evolution, prefrontal volume is be expected to take up a higher proportion of the brain in 
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humans than in non-human primates with smaller brains. In a recent paper, Barton and Venditti 
argued that the widely held assumption that human brain evolution involved relative expansion of 
the frontal lobes may lack support, and that “… unless one is willing to take seriously the hypothesis 
that lemurs have more of the qualities bestowed by the frontal cortices than do humans, or that 
llamas possess more than monkeys, it must be concluded that testing the hypothesis that any species 
is specialized for frontal functions (…) requires scaling to be taken into account.” (Barton and Venditti, 
2013) (p. 9001-9002). 
 
2.4 Principles of regional cortical age-changes: Default Mode Network 
Interestingly, the more recently described default mode network (DMN) is almost completely 
encapsulated in the high-declining regions in Figure 2. DMN (Raichle et al., 2001) has received much 
attention recently (Snyder and Raichle, 2012), and its robust appearance across studies indicates that 
it plays a major role in human brain function (Buckner, 2012). For a delineation of some important 
DMN regions, see Figure 10. The DMN consists of a specific set of brain areas that decrease activity 
during performance of a wide range of tasks, and that are typically also active also during periods of 
rest or introspection (Snyder and Raichle, 2012). The different DMN structures are densely 
interconnected to each other and limbic structures by polysynaptic connections, with few 
connections to sensory and motor areas (Binder et al., 2009, Buckner, 2012). Structural and 
functional aspects of DMN are affected both in normal aging (Lustig et al., 2003, Andrews-Hanna et 
al., 2007, Addis et al., 2011) and AD (Greicius et al., 2004, Walhovd et al., 2010, Jones et al., 2011). 
DMN maps onto a network of core brain areas involved in episodic memory and imagination 
(Buckner and Carroll, 2007, Schacter et al., 2007), and is therefore highly relevant for the 
understanding of episodic memory problems in aging. Recent normative studies (Laird et al., 2009, 
Andrews-Hanna et al., 2010) have pointed to at least seven important regions within the default 
mode and episodic memory/ simulation network: rostral middle frontal, inferior parietal cortex and 
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middle temporal cortex on the lateral side, and medial orbitofrontal cortex, precuneus, entorhinal 
cortex and the hippocampus on the medial side (although the roles played by hippocampus and 
enthorinal cortex are debated (see (Nyberg et al., 2010a, Squire et al., 2010, Cooper et al., 2011, Yeo 
et al., 2011)). Early on it was suggested (Andreasen et al., 1995) that the network primarily consists 
of association cortices that have undergone especially large evolutionary changes from nonhuman 
primates to humans, have the most complex columnar organization and are slow to reach mature 
levels of myelin (Catani and ffytche, 2005). However, while this is true for some of the structures 
involved, especially on the lateral surface as shown above, a characterization of the DNM structures 
overall as unique to higher-order evolution would not be correct. Rather, some of these structures, 
such as the hippocampus, the entorhinal cortex and the retrosplenial cortex, share considerable 
similarities, likely both structurally and functionally, across several species. These structures belong 
to the medial temporal lobe DMN subsystem (Andrews-Hanna et al., 2010), critical for the ability to 
navigate in space in many species. At the same time, this is a capability that is affected relatively 
early in AD. Also the medial parietal cortex, including the precuneus, belonging to the midline core of 
the DMN in the same classification, has expanded relatively little during evolution (see Figure 9). 
Thus, there are considerable areas anatomically not overlapping across the DMN and evolutionary 
cortical expansion maps. Although DMN likely serves important functions for human cognition and 
mental life, resting-state networks overlapping the midline core of DMN have also been identified in 
monkeys. In a recent study, functional networks were directly compared between humans and 
monkeys, and both inter-species corresponding and human-specific networks were identified 
(Mantini et al., 2013). In sum, the theory of DMN as localized in evolutionary recent cortical areas 
does not seem justified. 
 
Naturally, DMN is a prime target for investigation into the structural correlates of reduced cognitive 
function in both normal aging and AD. As can be seen from Figure 10, rates of yearly cortical volume 
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reduction in these areas are higher than in most other cortical regions, indicating that the DMN is 
vulnerable to normal aging. This is also true for the posterior cingulate/ retrosplenial/ precuneus and 
MTL, which have been relatively low-expanding in evolution. A speculative suggestion may be that 
these areas support fundamental aspects of episodic memory that would have large adaptive 
benefits during early evolution, such that they are relatively well developed even in non-human 
primates. Recent studies have compared resting state (Hutchison and Everling, 2012) and task-
related functional networks between humans and non-human primates (Mantini et al., 2012, 
Miyamoto et al., 2013), showing functionally correspondent networks across species. Corballis 
recently argued for the existence of evolutionary continuity in the capacity for mental time travel 
(Corballis, 2013a, b), which is closely connected to hippocampal and medial parietal cortical function. 
Although the discussion of whether this capacity exists in non-human primates is far from settled 
(Suddendorf, 2013), a natural conclusion from available evidence is that DMN is vulnerable to age-
changes for reasons not grounded in evolutionary expansion.  
 
Several studies have shown that longitudinal brain changes especially in MTL are correlated with 
changes in cognitive capacities, episodic memory function in particular (Rodrigue and Raz, 2004, 
Murphy et al., 2010, Persson et al., 2012, Fjell et al., 2013d, Nyberg et al., 2012). Thus, the DMN 
seems to provide a better account of the distribution of structural cortical changes in normal aging 
than the frontal or the “last in, first out” theories. Of special interest is the vulnerability of DMN to 
AD (Lustig et al., 2003), and the high overlap between DMN and areas of Aβ deposition and PET-FDG 
hypo metabolism (Buckner et al., 2005). We discuss this in more detail in Section 4.  
 
[Insert Figure 10 about here] 
 
3. Normal aging versus Alzheimer’s Disease: How to tell the difference? 
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Age-related dementia typically has a slow and gradual onset, with atrophy manifest years in advance 
of clinical symptoms (Davatzikos et al., 2009, Jack et al., 2010a, Jack et al., 2013). Some have even 
suggested that cortical decline in aging is caused by undetected disease and is not a feature of 
normal aging (Burgmans et al., 2009). An important implication of the apparent temporal gap 
between detectable cerebral and cognitive expression of dementia is that cases with undetected 
disease in presumably normal samples could bias inferences about normal brain aging (Sliwinski and 
Buschke, 1999). This is a particular concern since the proportion of elderly with undetected 
neurodegenerative disease is expected to increase with the age of the population, potentially leading 
to invalid conclusions of accelerated age-related decline in cortical areas vulnerable to disease 
pathology, especially the entorhinal cortex and hippocampus (Braak and Braak, 1985, Jack et al., 
1997, McDonald et al., 2009). However, it is also possible that stringent screening criteria could result 
in an over-representation of very high-functioning elderly in convenience samples (Nyberg et al., 
2010b), thereby reducing the amount of incipient dementia in aging-studies of the oldest old. The 
contribution of latent pathology to age-related decline in apparently normal aging thus remains an 
open question. However, differences in AD biomarkers, such as patterns of atrophy and amyloid 
deposition may shed light on this issue.  
 
The pattern of atrophy in AD is not random, but usually evolves slowly, following a specific pathway 
that first involves the entorhinal cortex and the hippocampus, then spreads out to association areas 
in medial parietal, lateral temporal and frontal regions, eventually affecting all regions of cortex . In 
Figure 11, rate of atrophy in healthy controls versus patients with MCI or AD from ADNI is shown. 
Even at the stage of MCI, annual atrophy is several times higher than in normal aging, with further 
increases in atrophy rate with progression to a full AD diagnosis. 
 
[Insert Figure 11 about here] 
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The organized pattern of brain changes in early AD can be used to differentiate between non-
demented elderly with lower vs. higher risk of progression to MCI or AD (Driscoll et al., 2009, McEvoy 
et al., 2009, McEvoy et al., 2011). For instance, Driscoll and colleagues identified a pattern of brain 
changes typical for AD patients, including temporal and orbitofrontal cortex, and argued that the 
differential patterns of decline in participants who subsequently developed MCI differed from that of 
participants who remained cognitively stable. The finding that both those who progress to AD and 
those who remained cognitively stable showed accelerated tissue loss indicates that atrophy does 
not necessarily signify impending dementia, and thus may not necessarily reflect latent AD. Likewise, 
McEvoy and colleagues used linear discriminant analysis to identify a pattern of regional atrophy by 
comparing healthy controls with AD patients, and found accelerated atrophy in the temporal cortex, 
isthmus of the cingulate and orbitofrontal cortex. These results could later be used to predict 
conversion to AD in ADNI’s MCI participants.  
 
These two examples show that magnitude of atrophy in collections of brain areas can be used to 
distinguish normal aging from AD. Still, when looking at atrophy maps in normal aging, e.g. Figure 2, 
it is evident that temporal regions, both medial and lateral, are among those that decline the most. 
Even though hippocampus and entorhinal cortex are the areas that best distinguish AD from controls 
in terms of atrophy rates (Fjell et al., 2010b), and these temporal areas figured prominently in the AD 
risk patterns in the studies described above, low-risk elderly also show accelerated change in these 
areas. Similar results have been reported for hippocampus in several independent studies (Driscoll et 
al., 2009, Fjell et al., 2009a, Raz et al., 2010, Pfefferbaum et al., 2013). Thus, MTL atrophy is common 
in normal aging and AD. This is illustrated in Figure 12 (Fjell et al., 2013a). When the large differences 
in magnitude of atrophy are removed by standardizing the atrophy maps within each diagnostic 
group, two interesting features become apparent. First, both the low-risk healthy elderly and MCI/ 
22 
 
AD patients are characterized by elevated atrophy in the temporal lobes, medially and laterally. 
Atrophy in the temporal lobe exceeded two standard deviations above mean cortical atrophy in all 
groups. A second interesting feature is the relatively high level of atrophy in the orbitofrontal cortex 
in the normal controls. In the patients, these areas do not stand out as more atrophic than the rest of 
the cortex. Thus, the fronto-temporal pattern of atrophy in the low-risk elderly is replaced by an even 
more distinct temporal pattern of atrophy in the patients. Relatively high levels of atrophy in the 
medial parietal cortex, i.e. precuneus and posterior parts of the cingulate, were also seen across 
groups. Of interest, the accelerated prefrontal atrophy in the healthy group overlaps with one of the 
cortical regions that has expanded the most during evolution, while not being among the regions 
most vulnerable to early AD. Thus, it seems that evolutionary expansion, even with the discrepancies 
found in the medial temporal cortex, characterizes the brain changes in healthy aging better than the 
atrophy seen in early AD.  
 
[Insert Figure 12 about here] 
 
The vulnerability of the temporal lobes in aging and AD naturally prompts the question of whether 
brain-changes observed in non-demented older adults are in part caused by undetected 
neurodegenerative processes of an Alzheimer type. At age 79, the probability of significant AD 
neuropathological changes in the brain is 30-40% , but the likelihood of having been diagnosed with 
dementia due to AD is only 15% (Nelson et al., 2012). Subtle cognitive symptoms have been 
identified more than 10 years before dementia diagnosis (Elias et al., 2000), and the currently 
popular hypothetical biomarker model suggests that brain changes are detectable before the first 
cognitive symptoms (Jack et al., 2010a, Jack et al., 2013). Thus, the question of whether brain 
atrophy in typical AD areas, i.e. the temporal lobes, can be attributed to preclinical manifestations of 
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the disease is not a trivial one. However, there are several pieces of evidence indicating that these 
brain changes indeed constitute a part of normal, non-disease specific aging.  
 
First, Resnick and colleagues followed 92 healthy elderly from the Baltimore Longitudinal Study of 
Aging for four years, and found significant reductions in brain volume in all cortical lobes  (Resnick et 
al., 2003). Of most interest, these changes were also seen in a subgroup of 24 very healthy 
participants who experienced no medical condition or cognitive impairment four years after the 
initial examination. The authors argued that the uniformity of tissue loss across individual 
participants indicated that these were not pathological changes associated with preclinical dementia, 
unless all participants had been in such a preclinical stage, which is highly unlikely. Thus, these results 
constitute evidence that tissue loss in older adults does not need to be caused by undetected, 
preclinical dementia. A similar conclusion was drawn in the later study by the same group where 
participants were followed for periods up to ten years after baseline, furthering ruling out the 
possibility that all participants were in a preclinical stage of AD (Driscoll et al., 2009). 
 
Second, in our own work, we have focused specifically on the fate of AD-prone areas in healthy 
controls, and attempted to disentangle normal age-changes from changes related to preclinical AD. 
We quantified one-year cortical thinning in 138 normal elderly from ADNI, and found the expected 
reductions in the temporal lobe, including the medial temporal lobes and the entorhinal cortex (Fjell 
et al., 2013d). From the full sample of non-demented participants, subsamples with very low 
probability of AD were identified. A group of cognitively “super-stable” participants (n = 18) were 
selected based on a lack of decline over two years on scores of two clinical measures and seven 
neuropsychological tests. Another group was selected based on their negative CSF Aβ test (n = 28). A 
final group consisted of those that were both amyloid negative and negative for APOE ε4 (n = 22). 
Interestingly, rate of cortical thinning in the entorhinal cortex did not differ between the full sample 
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of non-demented older adults and the different low-risk groups. This further supports the view that 
brain changes in older adults are not necessarily related to early AD-processes, but can be part of the 
normal aging process, even in areas prone to early AD. Interestingly, in the 94 participants with no 
change over two years in the two clinical measures, the entorhinal changes correlated with changes 
in memory performance over time, suggesting that non-AD mechanisms in AD-prone areas may still 
be causative for cognitive decline. With longer follow-up data from ADNI more recently available, 
investigation of the same participants up to four years after the initial exam has shown that 
significant entorhinal and hippocampal atrophy can be detected in groups of elderly at very low risk 
of AD defined by clinical neuropsychological, genetic and biomarker criteria (Fjell et al., 2013a). An 
independent study also identified small hippocampal volumes in a group of amyloid negative elderly 
(Knopman et al., 2013). Further, Oh et al found correlations between age and cortical volume and 
thickness, including in the medial and lateral temporal lobe, in healthy elderly even when amyloid 
status as indexed by PIB PET was used as covariate (Oh et al., 2013). Such results can be used to 
argue that brain atrophy in AD-prone regions can be a part of the normal aging-process. Of course, 
there is no guarantee that such changes are due to aging or non-AD pathology, and it cannot be ruled 
out that a component of the net loss may be due to very early AD in individuals stable over several 
years. Also, a danger associated with low-risk group analyses is that the power to detect differences 
in decline diminishes with the reduction in sample size. Still, demonstration of cortical atrophy in 
low-risk older adults makes a strong case that preclinical AD is not the only factor driving brain 
change in aging. 
 
4. Neuroplasticity in the aging brain – a critical vulnerability factor? 
If atrophy in normal aging does not reflect latent AD pathology, a critical question that must be 
addressed is why it is that AD-prone areas are also highly vulnerable to normal age-changes? These 
areas include not only the temporal regions, but regions around the medial parietal cortex (the 
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precuneus/ posterior cingulate/ retrosplenial cortex) – an area that is an important component of 
the DMN. One speculation is that areas characterized by high degree of life-long plasticity are those 
most vulnerable to detrimental effects of normal and pathological aging (Neill, 1995, Mesulam, 1999, 
Bufill and Carbonell, 2004, Rapoport and Nelson, 2011, Neill, 2012, Bufill et al., 2013). The pattern of 
effects may be explained by the special role of the medial temporal lobes and other parts of DMN in 
learning and memory, with high demands for life-long plasticity required for these cognitive 
functions (Aimone et al., 2010, Deng et al., 2010). For instance, neurogenesis in the hippocampus 
may be important for structural plasticity and network maintenance, and it has been suggested that 
altered neurogenesis in the hippocampus is an early critical event in AD (Mu and Gage, 2011). Down-
regulation of neurogenesis in the aged mouse brain has also been found (Lazarov et al., 2010). As 
neurogenesis in the adult brain is likely limited to the dendate gyrus of the hippocampus as well as 
the olfactory bulb, it is unlikely to be a main factor in the changes in brain and cognition associated 
with aging. However other mechanisms related to neuroplasticity could be at play in other age-
vulnerable regions. Dendritic spines may represent a primary site of structural plasticity in the adult 
brain, and spine plasticity seems to play an important role in long-term memory in rodents (Sanders 
et al., 2012). Dendritic spine plasticity in the prefrontal cortex is reduced in aged rodents (Bloss et al., 
2011), and spine density is likely reduced in aging (Jacobs et al., 1997, Esiri, 2007, Freeman et al., 
2008, Benavides-Piccione et al., 2013) (see Figure 13).  
 
Another interesting feature is that the medial temporal lobe structure dentate gyrus is the only site 
of adult human neurogenesis besides the olfactory bulb (Eriksson et al., 1998, Lotsch et al., 2013). 
This is different from other primate species, where new neurons can be added throughout life in 
regions of the neocortex (Gould et al., 2001, Bernier et al., 2002, Vessal and Darian-Smith, 2010). 
Thus, the medial temporal lobe is an evolutionary old and at the same time a neuroplastic area 
within an otherwise much more developed and expanded neocortex. The downside of being lone 
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areas involved in or surrounding this type of plasticity in the human brain may be increased 
vulnerability and accumulation of negative impacts through life. Lesions in the highly neuroplastic 
limbic system could then have consequences for association cortices with which they are reciprocally 
interconnected (Mesulam, 1999).  
 
Thus, although still highly speculative, it may be that certain brain regions are characterized by 
increased demands for life-long plasticity mechanisms, and that this makes them especially 
vulnerable to subtle lesions and pathology accumulating through life. The cost of maintained 
plasticity may be increased vulnerability to factors which can trigger cognitive decline (Bufill et al., 
2013). Perturbation of neuroplasticity has previously been proposed as a fundamental principle of a 
unitary theory that could potentially account for all clinical and neuropathological features of AD, on 
the assumption that amyloid depositions and neurofibrillary tangles are manifestations of the same 
underlying phenomenon (Mesulam, 1999). The potential for neuroplasticity is higher in the limbic 
system than in other parts of the cerebral cortex, which increases its vulnerability to neurofibrillary 
degeneration. A consequence of this view may be that late-onset AD is not a disease at all, but “the 
inevitable manifestation of a failure to keep up with the increasingly more burdensome work of 
plasticity” (Mesulam, 1999) (p. 526). This is in line with a systems vulnerability view on aging and AD, 
where critical networks are subject to various negative impacts, aging in particular, rather than being 
selectively targeted in AD (Jagust, 2013). 
 
Somewhat related to the concept of plasticity is an idea based on the observed overlap between 
regional distribution of deposition of amyloid and the DMN that the level of brain activity itself may 
be causally related to amyloid deposition (Jagust and Mormino, 2011, Buckner, 2012). Amyloid 
depositions are part of the histopathological definition of AD, but the role of amyloid in normal aging 
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and in the transition from normal aging to neurodegeneration is still poorly understood, and the 
target of several large research initiatives  
 
[Insert Figure 13 about here] 
 
5. Amyloid and brain changes in non-demented older adults: preclinical dementia or a role in 
normal aging? 
Amyloid depositions are part of the histopathological definition of AD, and thus much weight is put 
on in vivo biomarkers of amyloid in contemporary AD research, as reflected in the NIA-AA proposed 
diagnostic guidelines for Alzheimer’s disease and its preclinical stages (Jack et al., 2011, Sperling et al., 
2011a). The role of amyloid in neurodegeneration is envisioned to be very early in the cascade of 
detrimental events that culminates with dementia and a clinical diagnosis of AD (Jack et al., 2010a, 
Jack et al., 2013). Current models posit that brain atrophy in AD progresses years before clinical 
symptoms (Jack et al., 2011, Sperling et al., 2011a), but that nerve cell degeneration is downstream 
from even earlier causative events, especially abnormal processing of amyloid-β peptides (Goedert 
and Spillantini, 2006, Jack et al., 2010a). It has been suggested that, once initiated, the 
neurodegeneration in AD progresses independently of its amyloid-trigger, leading to the commonly 
expressed concern that the therapeutic window for anti-amyloid drugs may close when 
neurodegeneration has started to accelerate (Sperling et al., 2011b). Thus, it is absolutely necessary 
to better understand the relationship between amyloid, brain integrity and memory in healthy 
elderly. It has been suggested that older adults with normal cognitive function despite AD-related 
pathology should be the focus of intense investigation, because they may be in earliest phases of AD 
(Jagust, 2013). The difficult question is then: What amyloid-related changes in brain and cognition 
represent AD-related pathology, and what, if any, such changes can be expected as part of the 
“normal” aging-process? 
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Aβ-atrophy correlations have been demonstrated in MCI/AD patients(de Leon et al., 2006, Fjell et al., 
2010b) and normal controls (Storandt et al., 2009, Fjell et al., 2010a, Becker et al., 2011, Fortea et al., 
2011, Arenaza-Urquijo et al., 2013b), eliciting debate about whether brain atrophy related to amyloid 
in presumably healthy elderly signifies early AD-related changes (Becker et al., 2011, Fortea et al., 
2011, Shim and Morris, 2011, Sperling et al., 2011a) or whether they may be part of the normal aging 
process (Fjell and Walhovd, 2013b). This pertains directly to the question of whether the factors that 
drive atrophy in AD also play a role in normal aging. In ADNI, relationships between CSF levels of Aβ1-
42 and cortical atrophy have been found in MCI patients (Schuff et al., 2009, Fjell et al., 2010b, Jack et 
al., 2010b, Tosun et al., 2010) and controls (Fjell et al., 2010a, Schott et al., 2010). In the controls, 
however, CSF Aβ1-42 predicts atrophy only in the subgroup of participants with very low Aβ1-42 levels 
(an indication of a high level of Aβ deposition in the brain).  In these participants, strong Aβ1-42 - 
atrophy correlations can be observed in large areas of the cortex, but not MTL. This is shown in 
Figure 14. In MCI, the correlations are weaker, and restricted to the temporal lobes, medial parietal 
cortex and posterior cingulate. Thus, the pattern of correlation is almost non-overlapping between 
the healthy older adults and the MCI patients. In contrast, no relationship between atrophy and CSF 
p-tau levels can be seen in the healthy older adults, while the expected correlation between p-tau 
and temporal atrophy can be seen in MCI patients. Interestingly, recent studies from ADNI have 
shown interactions between p-tau levels and Aβ1-42 in clinical decline (Desikan et al., 2012) and 
entorhinal atrophy (Desikan et al., 2011) in non-demented elderly. In general, the anatomical 
distribution of tau pathology, initially restricted to MTL, fits better with the spreading of atrophy in 
AD, and also with the earliest cognitive symptoms of memory and navigation problems. 
Histopathological data indicate that accumulation of tau-related pathology is an earlier event than 
Aβ deposition (Braak and Braak, 1997a, b). An interesting feature is that Aβ is only modestly related 
to age, while at least levels of total tau increases substantially. As age is the number one risk factor 
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for AD, understanding brain events that also increase in intensity with age would set us in a position 
to better understand why aging plays such a prominent role in AD development. A recent study 
found that MTL tangle formation in non-demented elderly was independent of neuritic plaques, and 
proposed an age-related, non-amyloid process contributing to this (Mungas et al., 2014). In addition, 
they suggested that a primary amyloid-based AD process would make the largest contribution to MTL 
tangles. Other studies have also demonstrated MTL tangles without neuritic amyloid plaques (Nelson 
et al., 2009). Thus, there may be both direct amyloid-independent and indirect amyloid-dependent 
processes causing tangle formation, leading to cerebral and cognitive decrements in aging. Age-
related changes in tangle formation in MTL could contribute to explain the high levels of MTL atrophy 
observed even in healthy elderly at low AD-risk and the consequent decline in episodic memory. 
 
[Insert Figure 14 about here] 
 
The relationship between Aβ and tangle formation is also closely related to the discussion of which 
brain changes in aging result from early AD-related processes and which are AD-independent. Aβ-
atrophy correlations in cognitively stable older adults have been interpreted as reflecting early AD 
(Tosun et al., 2010, Becker et al., 2011, Fortea et al., 2011, Shim and Morris, 2011, Sperling et al., 
2011a). However, the healthy older adults shown in Figure 14 are not on the verge of converting to 
MCI or AD, as evidenced by their status as normal controls two years later, and their normal levels of 
atrophy and normal memory function (Fjell et al., 2010a). The few other studies testing Aβ-atrophy 
correlations in healthy elderly in vivo generally show the same lack of medial temporal lobe-
relationships in the cerebral cortex, especially in entorhinal cortex (Storandt et al., 2009, Fjell et al., 
2010a, Tosun et al., 2010, Becker et al., 2011, Oh et al., 2011, Arenaza-Urquijo et al., 2013b) (see 
Figure 15 for examples), even though the results sometimes are complex (Bourgeat et al., 2010, 
Chetelat et al., 2010a, Chetelat et al., 2010b). In contrast, Aβ-atrophy correlations in MCI are found 
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mainly in the temporal lobe, laterally and medially. Correlations between  Aβ and hippocampal 
volume (Mormino et al., 2009, Arenaza-Urquijo et al., 2013b) or atrophy (Fjell et al., 2010a) have 
been observed, but when compared to correlations with other subcortical structures, Aβ-atrophy 
relationships often do not stand out as especially strong (Fjell et al., 2010a). This was also found in a 
longitudinal study from the Australian Imaging, Biomarker and Lifestyle Study of Ageing (AIBL). 
Healthy controls with higher levels of amyloid deposition showed more hippocampal atrophy, but 
also more total gray matter loss (Villemagne et al., 2013). As recently reviewed, significant 
hippocampal atrophy in amyloid-positive cases has been inconsistently observed (Chételat et al., 
2013). 
 
[Insert Figure 15 about here] 
 
One way to reconcile these findings could be to hypothesize that Aβ reflects processes related to 
brain changes in elderly without AD-symptoms, but that it is only when these processes impact MTL 
that cognitive decline of the sort observed in early AD/ MCI becomes evident. As described above, 
MTL plays a special role in learning and memory, with high demands for life-long plasticity and 
neurogenesis required for these cognitive functions. Rodent research has shown that Aβ, although 
usually in extremely high doses, can affect synaptic function by modulation of maturation and 
plasticity of newborn neurons in hippocampus (Biscaro et al., 2009, Lilja et al., 2013). Thus, the 
impact of Aβ on the temporal lobes may cause malfunction that cannot be compensated for by 
mechanisms of neural plasticity elsewhere in the brain. Although the atrophy-driving mechanisms 
may be related to Aβ, the causal role of amyloid in neurodegeneration in healthy older adults 
remains an open question. Such an account may call for a revision of the prevailing view of amyloid 
biomarkers in normal aging and AD, in that healthy aging and AD may have partly common neural 
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mechanisms for brain atrophy (see also (Glass and Arnold, 2012)). A critical issue may thus be the 
regional distribution of Aβ, not only the amount (see Figure 16).  
 
[Insert Figure 16 about here] 
 
Several authors have pointed out the overlap between the DMN and the distribution of amyloid (for 
a review, see (Buckner, 2012)), and it has been suggested that lifelong patterns of neural activity lead 
to increased Aβ production and deposition (Jagust and Mormino, 2011). It has been demonstrated 
that synaptic activity increases amyloid-beta levels in mice (Cirrito et al., 2005), and that neural 
activity regulates the regional concentration of Aβ, which again drives local Aβ aggregation (Bero et 
al., 2011). Thus, the cognitive importance of DMN has been envisioned to cause its susceptibility to 
Aβ  (Buckner, 2012), p 11): “AD may be so devastating to higher cognitive function specifically 
because it targets brain systems expanded in the human brain and important to the default network, 
robbing the ability to remember and imagine. The clinical insight from this connection is that 
downstream consequences of normal basal activity and metabolism may facilitate AD pathology.” 
Further support for the neural activity – amyloid mechanism has come from recent research showing 
a relationship between brain aerobic glycolysis and Aβ (Vaishnavi et al., 2010, Vlassenko et al., 2010). 
Education is an often-used  proxy for cognitive reserve, which is defined as the ability to maintain 
cognitive function despite high levels of AD pathology.  (Stern et al., 1999, Stern, 2006, 2012). Higher 
education is typically regarded as facilitating the development or use of alternate strategies to cope 
with pathology. However, according to the activity-dependent amyloid accumulation view, the 
situation may be the opposite. Higher education itself could lead to the build-up of amyloid 
pathology through its effect of promoting  life-long intellectual activity.  
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This theory is intriguing, but prompts difficult questions: First, both targeted, experimental cognitive 
interventions (Engvig et al., 2010, Zatorre et al., 2012) and lifespan mental activity (Valenzuela et al., 
2008) are shown to have positive effects on brain atrophy and cognitive function in elderly. One 
study even found a relationship between self-reported lifespan cognitive activity and lower amyloid 
deposition as measured by Pittsburgh Compound-B (PiB) PET (Landau et al., 2012), and the authors 
suggested that “(…) lifestyle factors found in individuals with high cognitive engagement may prevent 
or slow deposition of β-amyloid, perhaps influencing the onset and progression of AD.” A recent study 
by Selkoe and colleagues found that enriched environments increased synaptic plasticity in the 
hippocampus and yielded better resistance to toxic effects of Aβ oligomers in wild-type mice (Li et al., 
2013). The researchers then went one step further, and showed that blocking the β2-adrenergic 
pathway hindered the positive effects of environmental exploration while stimulating β2-adrenergic 
signaling yielded the same benefits as environmental enrichment, thus providing a clue to one 
possible mechanism behind the often-reported positive association between intellectual activity and 
cognitive function. The idea that neural activity itself may initiate a cascade of neurodegenerative 
events needs to be reconciled with such findings.  
 
Second, even if the overlap between DMN and early Aβ deposition, as evidenced by amyloid imaging, 
is causally related to the high activity of certain parts of the DMN (Jagust and Mormino, 2011, 
Buckner, 2012), it yet not clear whether the life-long pattern of brain activity is higher in the areas 
with higher Aβ depositions, e.g. the medial posterior parietal cortex, than in the areas with less, such 
as the medial temporal lobes. The hippocampus and surrounding cortices are involved in encoding of 
all new information, consolidation of memories, episodic memory retrieval and spatial navigation 
(Buzsaki and Moser, 2013), and even show a high level of activity during sleep (Grosmark et al., 2012). 
As can be seen in Figure 14, Aβ deposition is detected in histopathological studies in the medial 
temporal lobes before advanced AD (Braak stage A), but is usually not found to be among the first 
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regions to show increased amyloid deposition by amyloid PET imaging in non-demented elderly 
(Sojkova et al., 2011, Mormino et al., 2012). If cognitive activity is directly related to amyloid 
production and later deposition, we need to understand why amyloid deposition is not more evident 
in these areas in early phases. One explanation could be that cognitive activity increases brain 
efficiency –people who perform tasks as experts or who are better trained actually may use fewer 
neural resources. Thus, people who remain cognitively active throughout life develop more efficient 
ways of performing mental tasks, and therefore produce less Aβ (Jagust, personal communication). 
This could possibly unite the seemingly contradictory findings of increased Aβ production with 
synaptic activity combined with possibly lower levels of Aβ deposition with sustained intellectual 
activity. Another possibility is that amyloid accumulation in non-demented elderly actually is higher 
in the medial temporal lobes than in most other parts of the brain. This was suggested by a recent 
study of network properties of amyloid accumulation in healthy elderly with low amyloid levels, 
where it was argued that accumulation begins in the amygdala-orbitofrontal-hippocampus formation, 
before extending to entorhinal cortex and  the posterior medial and lateral temporal pole, the medial 
parietal cortex and the medial and lateral prefrontal cortex (Sepulcre et al., 2013). Recent results 
from AIBL also indicated substantial longitudinal change in amyloid deposition in the temporal lobe in 
healthy elderly, even in those with initially little or no detectable amyloid burden (Villain et al., 2012). 
Still, amyloid deposition as detected by PIB PET generally seems to be most intense in posterior 
medial parietal cortex and medial frontal cortex. 
 
Finally, although intellectual activity has been shown to have positive effects on brain biomarkers in 
some studies, there are discrepant findings, and a firm relationship between intellectual activity and 
amyloid deposition has not yet been established. Results from the large EClipSE (Epidemiological 
Clinopathological Studies in Europe) initiative did not provide evidence in favor of any relationship 
between education and amyloid deposition. A relationship was found between education, reduced 
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dementia risk and larger brain weight at death, but with no correlation between education and 
neurodegenerative or vascular pathologies (Members et al., 2010). Interestingly, higher education 
levels reduced dementia risk largely independent of severity of pathology, by mitigating the impact 
of pathology on the clinical expression of dementia before death, consistent with the cognitive 
reserve hypothesis. A recent publication from the Mayo Clinic Study of Aging did not find any 
relationship between amyloid deposition, glucose metabolism or hippocampus volume and lifetime 
or current intellectual activities (Vemuri et al., 2012). The relationships may be complex and affected 
by several variables. One study found that the relationship between cognitive function and AD 
histopathological markers was modified by the participants feeling of purpose in life (Boyle et al., 
2012). 
 
Another issue is that there is growing agreement that Aβ accumulation in sporadic AD is more related 
to decreased clearance than increased production (DeMattos et al., 2004, Mawuenyega et al., 2010, 
Castellano et al., 2011), in contrast to increased Aβ production seen in familial AD (Scheuner et al., 
1996). Thus, it may not be increased Aβ production that is the most relevant factor for amyloid 
deposition, but rather the ability of the brain to keep the Aβ peptides soluble (Robakis, 2010). In sum, 
we still lack convincing evidence for a relationship between amyloid deposition and intellectual 
activity in humans. 
 
To summarize, regions with relatively high mental activity are parts of the heteromodal cortex, 
supporting complex cognition, with a complex architecture and high functional connectivity, with 
some being late maturing in development and high-expanding in evolution. These areas also show 
higher levels of atrophy in aging (see Figure 9). Interestingly, prefrontal cortex is high-expanding in 
evolution and shows high levels of atrophy in normal aging, but is not among the most vulnerable 
regions in AD. Degeneration in these different age-vulnerable regions likely has a multitude of causes 
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that may affect deposition of amyloid, through increased production or through processes causing 
reduced ability to prevent oligomerization. The chain of causation is still unknown, however. For 
instance, with cerebral amyloid angiopathy, amyloid deposition is found in the inner walls of blood 
vessels in the brain. Cerebrovascular diseases, e.g. small vessel disease with accompanying cerebral 
microbleeds, thus increase the levels of deposited amyloid in the brain detected by PiB PET (Park et 
al., 2013). However, the cause of atrophy and degeneration could be directly related to the vascular 
problems, not amyloid deposition per se. The causal direction between vascular factors and amyloid 
accumulation is not yet established, and both are related to APOE ε4 (Song et al., 2004). Vascular 
disease risk factors, such as hypertension are also risk factors for AD and have been shown to affect 
brain structure (Raz et al., 2005, Salat et al., 2012, Jacobs et al., 2013) and amyloid accumulation 
(Rodrigue et al., 2013) in non-demented elderly and AD patients (Grimmer et al., 2012). Atrophy in 
these areas in normal aging may be caused by amyloid-independent events, while a gradual increase 
in deposition of amyloid may still be seen over time in the same areas. This may or may not be the 
same mechanisms observed in AD. It has been argued that the important task is not to decide 
whether the age-changes observed in these areas are disease-related, but to attempt to understand 
the fundamental mechanisms by which they occur (Jagust and Mormino, 2011). This will have 
implications for a number of diseases and conditions associated with aging. 
 
Since increased amyloid deposition is observed in AD, related to brain atrophy in both patients and 
healthy elderly, and has a preference for deposition in regions supporting complex cognitive 
functions like episodic memory (Buckner, 2012), one could expect amyloid levels to be related to 
cognitive function in older adults. Testing the relationship between amyloid levels and cognitive 
function has been a very active area of research, but the results so far have been conflicting, with 
some studies finding modest relationships while others do not. In a recent meta-analysis, Hedden et 
al. analyzed amyloid-cognition relationship across 34 independent studies of almost 3500 subjects 
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(Hedden et al., 2013). Episodic memory function was related to amyloid burden, with a correlation 
of .12, while executive function and global cognition correlated 0.08 and 0.09. The authors concluded 
that amyloid levels have small but nontrivial associations with cognitive function in older adults.  
 
An important consideration in the interpretation of the in vivo biomarkers of amyloid is that they 
may not be sensitive to the most relevant form of amyloid. Both CSF levels of Aβ1-42 and amyloid 
imaging with PIB PET reflect fibrillar Aβ levels and amyloid plaque load in the brain (Blennow et al., 
2010). Soluble oligomeric forms of Aβ may be more toxic than fibrillar Aβ (McLean et al., 1999), but 
are very difficult to measure reliably in CSF (Rosen et al., 2013). Consequently, to be amyloid 
negative based on in vivo PET imaging or CSF does not guarantee that there are not malign amyloid-
processing ongoing in the brain. It has been suggested that there actually could be several interacting 
pools of amyloid, with a large insoluble pool that is derived from a constantly turning over smaller 
soluble pools (McLean et al., 1999). 
 
6. Integration, summary and conclusion 
As argued above, we believe that a key element in understanding the borders between normal aging 
and the earliest stages of AD may be related to neuroplasticity; cognitive decline results when the 
brain is not able to compensate for accumulation of insults. The major genetic risk factor for AD, 
apolipoprotein ε4 (APOE), is related to neural plasticity. Higher levels of cognitive reserve, as 
indicated by education level and socio-economic status, are protective of AD diagnosis (Stern, 2012), 
as individuals with greater reserve can maintain cognitive function in the face of higher levels of 
brain amyloid (Members et al., 2010). The weak correlations between amyloid level and cognitive 
function suggest that other mechanisms, such as functional compensation, impact cognitive ability. 
The view that cognitive function can be maintained in aging by compensatory cognitive processes , 
and that decline is seen when a person is no longer able to compensate for reduced workings of 
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primary brain structures and circuits, has many supporters in contemporary research (Cabeza et al., 
2002, Park and Reuter-Lorenz, 2009, Grady, 2012). According to such a view, the magnitude of brain 
insults that can be accommodated without cognitive decline and progression to AD varies 
significantly between individuals, and a key to understanding why may be individual differences in 
neural and cognitive plasticity. Thus, it is important to understand the mechanisms that cause some 
older adults to develop AD and some to maintain cognitive function in spite of accumulated brain 
amyloid. To reach this aim, we need knowledge about individual differences in the relationship 
between the major neurocognitive events in AD. For instance, it is likely that the relationship 
between brain atrophy and amyloid load will vary substantially between different groups of 
participants (Fjell et al., 2010a), and this variation is likely not random. A key to improved diagnosis 
and prognosis, as well as to a better understanding of the disease mechanisms themselves, is to 
systematically map individual differences in the relationships between the major events in early AD. 
For instance, one approach to close in on the borders between healthy aging and AD is to study the 
characteristics of participants who show 
(a) Normal cognition and structural brain integrity as measured by MRI despite elevated levels of 
AD-biomarkers such as brain amyloid 
(b) Reduced cognition and brain integrity in AD-vulnerable regions with normal amyloid 
biomarkers 
(c) High levels of brain maintenance as measured by structural and functional neuroimaging  
(Nyberg et al., 2012) 
 
There is a dearth of studies focusing directly on the relationship between brain plasticity and aging- 
and AD-related biomarkers, such as intervention studies with systematic mapping of structural and 
functional brain characteristics in combination with amyloid imaging. Such studies would have the 
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potential to elucidate the relationship between cognitive function, brain integrity and mechanisms of 
cognitive and neural plasticity on the borders between normal aging and the earliest phases of AD. 
 
Several overarching principles of age-vulnerability have been proposed, including the “last in, first 
out” hypothesis. These principles only partially fit existing evidence, as for instance the medial 
temporal lobes are vulnerable to age-changes but relatively low-expanding in evolution. So far, the 
best overlap seems to be between cortical age-vulnerability maps and the DMN. As shown in the 
present review, cortical age-related reductions are often found in AD-prone areas, even in those 
individuals at low risk of AD. We argue that these structural changes are an inevitable part of the 
normal aging process, and not necessarily related to neurodegenerative disease. It is likely that the 
vulnerability of these areas to normal age-changes contributes to their vulnerability to pathological 
processes involved in AD. The background for this idea is that age affects the brain independently of 
AD, and there is a growing number of proponents of the view that it is important to understand age-
related changes to better understand AD: Herrup has developed a patho-physiological model for AD 
starting with age as the prime risk factor (Herrup, 2010), Jagust suggested that as brain systems may 
be vulnerable to aging in “in the absence of even subtle disease”, and that research should thus focus 
on fundamental causes of neural system vulnerability rather than solely on AD-specific degeneration 
(Jagust, 2013), and Khachaturian proposed that we should focus less on single etiological factors and 
rather study the full spectrum of pathogenesis in favor of a system-level approach (Khachaturian, 
2011). One idea may be that regions characterized by a high degree of plasticity are vulnerable to 
normal aging, which renders them even more susceptible to AD-pathology. With the normalcy-
pathology homology as starting point, studying the brain regions that are vulnerable to both aging 
and AD may allow us to disentangle disease-specific mechanisms from normal age-related events. 
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Figure legends 
Figure 1 Longitudinal episodic memory decline in aging 
Left panel: By using a random-effects pattern-mixture model, Josefsson and colleagues (2012), found 
individual differences both in initial memory scores (offset at time 0) and change over time in their 
large sample (n > 1500) of initially healthy participants, with some maintaining their functional level 
(18%), some showing age-average decline (68%), while some declined (13%). The researchers were 
able to identify environmental and genetic factors predicting group membership. Right panel: 
Correcting for selective attrition reveal a much steeper decline in episodic memory with increasing 
age than analyzing the full sample of available data. Figures modified from Josefsson et al. (2012). 
 
Figure 2 Longitudinal cortical volumetric reductions in aging 
Upper panel shows annual percent volume reduction of the cerebral cortex in a longitudinal sample 
of 132 healthy elderly (55-91 years at baseline) from ADNI (Alzheimer’s Disease Neuroimaging 
Initiative). Lower panel shows the same data, but the values have been re-scaled to yield a mean of 
zero and a standard deviation of one, to allow better visualization of regional distribution of change. 
Blue-cyan colors represent areas that are reduced more in one year than the rest of the cortex, while 
red-yellow colors represent areas of less than average reduction. The often-observed fronto-
temporal pattern of relative increased atrophy is evident, with medial parietal cortex/ posterior 
cingulate as additional regions with high rates of atrophy in aging. Data from (Fjell et al., 2013a). 
 
Figure 3 Age-thickness correlations  
Correlations between age and cortical thickness in a healthy multi-site adult life-span sample (n = 
1100, age 18-94). Correlations exceed -.40 in large regions, approaching -.70 in the prefrontal and 
lateral temporal cortex. Data from (Fjell et al., 2012). 
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Figure 4 Accelerated entorhinal decline in aging 
Cross-sectional estimates of annual rate of cortical thinning in the entorhinal cortex across the adult 
life indicate a marked increase in atrophy from 50 years. Age-related acceleration of decline in 
elderly has been confirmed with longitudinal data. Data from (Fjell et al., 2012). 
 
Figure 5 Life-span trajectories of volumetric reductions 
Cross-sectional estimates of adult life-span trajectories of total cerebral cortex volume and total 
hippocampal volume. Volume is expressed in units of standard deviations. Data from (Fjell et al., 
2013c). 
 
Figure 6 Cross-sectional vs. longitudinal results 
Left panel shows percentage annual change in cortical thickness measured longitudinally in a sample 
of healthy elderly (n = 207, 60-93 years). The right panel shows percentage annual change in cortical 
thickness estimated cross-sectionally in the same sample of participants. As can be seen, the 
apparent thickening of the anterior cingulate cortex in the cross-sectional analyses is not confirmed 
by the longitudinal results, indicating that this likely arises from issues with selective sampling. Also, 
estimated change is smaller in the cross-sectional compared to the longitudinal results. In other 
respects, the results are more similar. Data from (Fjell et al., 2012). 
 
Figure 7 Different effects of age on cortical surface area, thickness and gyrification 
Different structural features of the cerebral cortex have different genetic architecture and are 
reflecting different neurobiological events. Cortical surface area, thickness and gyrification are all 
negatively related to age, but to a different degree and with somewhat different regional distribution 
of effects. The results are displayed on the white matter surface of the brain. Gyrification index is 
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defined as the ratio between the buried cortex and the visible, outer surface cortex. Data from 
(Hogstrom et al., 2012). 
 
Figure 8 Fronto-striatal vs. temporo-parietal networks 
While normal aging affects both a fronto-striatal network important for cognitive control and 
executive function (green structures), AD has additional effects on a temporo-parietal network 
important for episodic memory function (purple structures). 
 
Figure 9 Evolutionary expansion and volume decline in aging 
Upper panel shows regions of high vs. lower cortical expansion from macaque monkeys to humans 
(maps re-computed from (Hill et al., 2010)). Lower panel shows regions of high vs. lower volumetric 
reduction in aging (based on the data from Figure 2). There is overlap between evolutionary high-
expanding regions in temporal and frontal cortex and regions with high decline in aging. The right 
panel shows annual volumetric decline in regions of high (z > 0.5 SD), medium (-0.5 < z < 0.5) and low 
(z < -0.5) evolutionary expansion. As can be seen, annual decline in aging is related to degree of 
expansion during evolution (for all comparisons, p < .05, corrected).  
 
Figure 10 Aging of the default mode network 
Annual percentage change in brain volume for six selected areas of the default mode network (DMN) 
in 132 healthy elderly (based on data from Figure 2). Both the medial and the lateral DMN changed 
significantly more than the whole brain rate of 0.44% (mean atrophy in the medial DMN: 0.70%, t 
[131] = 4.75, p < 10-5; mean atrophy in the lateral DMN: 0.53%, t [131] = 2.10, p < .05). Compared to 
the average cortical change (not including hippocampus) of 0.39%, the age-vulnerability of DMN is 
even larger. 
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Figure 11 Differences in cortical atrophy rates between healthy elderly and Mild Cognitive 
Impairment/ Alzheimer’s Disease 
In mild cognitive impairment (MCI), rates of cortical volumetric reductions are more than double that 
seen in healthy aging across large areas of the cerebral cortex, and rates more than three times 
larger are seen in AD. Please note that the scale is different between MCI/ healthy and AD/ healthy 
to allow appreciation of the regional patterns of effects across groups. Data from the Alzheimer’s 
Disease Neuroimaging Initiative. 
 
 
Figure 12 Comparison of aging and Mild Cognitive Impairment/ Alzheimer’s Disease 
Comparison of the standardized pattern of atrophy in a group of APOE ε4 negative elderly with 
normal levels of CSF Aβ, mild cognitive impairment (MCI) and AD. Atrophy maps are standardized 
within each group by Z-transformation, yielding maps showing areas of more (blue-cyan) vs. less 
(red-yellow) atrophy for each group in terms of standard deviations. Thus, atrophy is scaled within 
group, and changes are relative to group means. Across groups, we see common patterns of 
standardized change in the lateral and medial temporal lobe (including the hippocampus, not shown), 
and a distinct pattern characterizing only healthy elderly in the prefrontal cortex, especially the 
orbitofrontal part. Figure from (Fjell et al., 2013a). Atrophy across the cortex in the healthy elderly 
and the AD patients correlated .81, showing substantial overlap in regional vulnerability. 
 
Figure 13 Dendritic spine morphology in aging 
Benavides-Piccione et al (2013) 3D reconstructed 8900 individual dendritic spines from layer III 
pyramidal neurons in the cingulate cortex from two male humans of age 40 and 85 years, using 
intracellular injections of Lucifer Yellow in fixed tissue. The left two panels show the 3D 
reconstruction of the complete morphology of each spine of an apical dendritic segment at 100 µm 
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distance from the soma, and the estimation of the spine volumes shown in color codes (0-1.345 µm3). 
The middle two panels show mean dendritic diameter and dendritic spine density in apical dendrites 
in the middle-aged and the older participant. The right two panels show examples of apical dendritic 
segments from the middle-aged and the older participants. The differences in spine morphology are 
easily seen. Figure modified with permission from (Benavides-Piccione et al., 2013). 
 
 
Figure 14 CSF biomarkers and regional atrophy in aging and MCI 
Upper panel: CSF biomarkers of Aβ and p-Tau, indexing brain levels of amyloid and tangle load, 
respectively, correlate with temporal atrophy in stable MCI patients from ADNI (n = 213). In contrast, 
the correlations between atrophy and Aβ in amyloid positive healthy elderly (Aβ1-42 < 175 pg/ ml 
(Fjell et al., 2010a)) are seen in other cortical areas exclusively. This may indicate that the 
relationship between atrophy and amyloid is different in healthy aging and MCI, and that the 
selective lack of relationship between amyloid beta and atrophy in the medial temporal lobe in 
controls may represent a key to understand why these participants have not progressed to AD. 
Lower panel: Histopathological maps from Braak and Braak, projected onto the same template brain. 
The topographical pattern of accumulated  amyloid in AD brains resembles the Aβ-atrophy 
correlations seen in MCI to a much larger extent than the Aβ-atrophy correlations seen in non-
demented elderly.   
 
Figure 15Selected studies on amyloid and cortical structure in non-demented older adults 
Representative studies of the relationship between amyloid levels (PiB PET or CSF Aβ) and cortical 
thickness (baseline) or cortical atrophy (longitudinal) in healthy elderly (Storandt et al., 2009, Fjell et 
al., 2010a, Tosun et al., 2010a, Becker et al., 2011, Arenaza-Urquijo et al., 2013b). Common for these 
studies was the use of anatomically unbiased surface-based cortical analyses using FreeSurfer 
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(surfer.nmr.mgh.hardard.edu). We extracted the effect sites from the published figures, and 
projected them onto the same standard brain to allow visual comparison of the results. For some, 
the colors of the effects were changed to aid discriminability between the different studies. The main 
conclusions are that Aβ levels are not related to cortical thickness/ atrophy on cognitively healthy 
elderly in typical AD areas in the medial temporal lobe (green box).  
 
Figure 16 A speculative model of Aβ-atrophy relationships in normal aging and MCI 
One speculative explanation for the discrepant Aβ-atrophy relationships in healthy aging vs. MCI (see 
Figure 12) would be to assume that lesions related to amyloid levels can occur in several places in the 
cortex in aging.  Lesions targeting the temporal lobe will tend to yield memory problems that are 
difficult to compensate for, increasing the likelihood of an MCI diagnosis. In contrast, lesions in other 
parts of the cortex are less directly related to memory problems and may also be easier to 
compensate for, thus reducing the likelihood of an MCI/ AD diagnosis. This would cause the observed 
discrepancy in regional distribution of amyloid-atrophy relationships between clinically normal older 
adults and MCI patients.  
 
 
















